NCT04616027View on ClinicalTrials.gov

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions
Diabetes Mellitus, Type 2Renal ImpairmentHealthy
Interventions
DRUG

PF-06882961 20 mg

PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami Hospital, Miami

55114

Prism Research LLC dba Nucleus Network, Saint Paul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY